A Study of Multiple Doses of LY3305677 in Healthy Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-27

Study Completion Date

2018-08-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purposes of this study are to determine:

* The safety of LY3305677 and any side effects that might be associated with it.
* How much LY3305677 gets into the bloodstream and how long it takes the body to remove it in healthy participants, including those of Japanese origin.
* The effect LY3305677 has on the body, particularly the effect on blood glucose levels.

This study will last approximately 17 weeks not including screening. Screening is required within 4 weeks prior to start of the study.

This study is for research purposes only and is not intended to treat any medical conditions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3209590 in Japanese Participants With Type 2 Diabetes

NCT03603704

Diabetes Mellitus, Type 2

COMPLETED PHASE1

A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus

NCT05086445

Diabetes Mellitus, Type 2

COMPLETED PHASE1

A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

NCT04586907

Healthy Type 2 Diabetes Mellitus

COMPLETED PHASE1

A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants

NCT06869018

Healthy Type 2 Diabetes Mellitus (T2D)

ACTIVE_NOT_RECRUITING PHASE1

A Study of LY2922470 in Healthy Participants and Participants With Diabetes

NCT01746017

Diabetes Mellitus, Type 2

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3305677

Escalating doses of LY3305677 administered by subcutaneous (SC) injection

Group Type EXPERIMENTAL

LY3305677

Intervention Type DRUG

Administered SC

Placebo

Saline solution administered by SC injection

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered SC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3305677

Administered SC

Intervention Type DRUG

Placebo

Administered SC

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Are overtly healthy males or females, as determined by medical history and physical examination
* Women not of child-bearing potential due to surgical sterilization confirmed by medical history or menopause
* Are first-generation Japanese or non-Japanese. First-generation Japanese is defined as the participant, the participant's biological parents, and all of the participant's grandparents are of exclusive Japanese descent and have been born in Japan
* Have a body weight of more than 54 kilograms (kg)

Exclusion Criteria

* Currently enrolled in a clinical study or have participated in a study within the past 3 months
* Have an abnormality in the 12-lead electrocardiogram (ECG) at screening
* Have history of pancreatitis
* Have known or ongoing psychiatric disorders
* Have undergone bariatric surgery or have used any drugs for weight loss
* Have a history of alcoholism
* Currently smoke more than 10 cigarettes a day

Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes